IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.281
EU - Europa 2.234
AS - Asia 1.662
SA - Sud America 19
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 10
OC - Oceania 7
Totale 7.224
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.245
CN - Cina 1.457
IE - Irlanda 868
FI - Finlandia 353
UA - Ucraina 275
DE - Germania 209
IT - Italia 196
SG - Singapore 169
SE - Svezia 130
GB - Regno Unito 77
FR - Francia 40
CA - Canada 36
RO - Romania 24
NL - Olanda 16
BE - Belgio 14
BR - Brasile 13
IN - India 12
RU - Federazione Russa 8
AU - Australia 7
EU - Europa 7
CH - Svizzera 6
MU - Mauritius 6
PL - Polonia 5
JP - Giappone 4
CZ - Repubblica Ceca 3
LA - Repubblica Popolare Democratica del Laos 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BG - Bulgaria 2
CL - Cile 2
EG - Egitto 2
HK - Hong Kong 2
LT - Lituania 2
LV - Lettonia 2
MY - Malesia 2
NG - Nigeria 2
VN - Vietnam 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BD - Bangladesh 1
CO - Colombia 1
EC - Ecuador 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
IQ - Iraq 1
KG - Kirghizistan 1
LK - Sri Lanka 1
NP - Nepal 1
PY - Paraguay 1
QA - Qatar 1
SA - Arabia Saudita 1
TR - Turchia 1
TW - Taiwan 1
Totale 7.224
Salva come PNG Salva come JPEG
Città #
Dublin 867
Chandler 643
Jacksonville 423
Nanjing 393
Ashburn 279
Boardman 260
Princeton 168
Nanchang 163
Lawrence 159
Beijing 139
Helsinki 135
Wilmington 121
Shenyang 116
Singapore 116
Changsha 111
Hebei 110
Medford 101
New York 95
Jiaxing 91
Ann Arbor 79
Shanghai 71
Tianjin 61
Hangzhou 58
Milan 37
Toronto 30
Woodbridge 29
Norwalk 28
Pavia 26
Seattle 26
Los Angeles 22
Timisoara 22
Washington 20
Fairfield 15
Brussels 14
Jinan 13
Verona 12
Auburn Hills 10
Falkenstein 10
Zhengzhou 10
Falls Church 9
Florence 9
Guangzhou 8
Ningbo 8
Pune 7
Rome 7
Des Moines 6
Taizhou 6
Frankfurt am Main 5
Monmouth Junction 5
Orange 5
Dearborn 4
Fuzhou 4
Gallarate 4
Paris 4
Reston 4
San Francisco 4
Shijiazhuang 4
Azzano San Paolo 3
Brugherio 3
Canberra 3
Dallas 3
Fano 3
Fiesole 3
Houston 3
Kunming 3
Lugano 3
Munich 3
Prague 3
Redwood City 3
Saint Paul 3
San Luis Obispo 3
Santa Clara 3
Tappahannock 3
Wayne 3
Amsterdam 2
Andover 2
Antony 2
Borås 2
Bremen 2
Buffalo 2
Cairo 2
Chicago 2
Colombo 2
Dronten 2
Genoa 2
Gießen 2
Groningen 2
Haikou 2
Hanoi 2
Harbin 2
Kemerovo 2
Krakow 2
Lagos 2
Lanzhou 2
Leawood 2
London 2
Manchester 2
Monza 2
Navi Mumbai 2
Ottawa 2
Totale 5.289
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 96
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 85
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 81
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 80
Blast phase of essential thrombocythemia: A single center study. 78
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 76
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 75
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 73
An insidious presentation of splenic marginal zone lymphoma 73
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 72
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 72
JAK2 (V617F) mutation in healthy individuals 71
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 71
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 70
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 68
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 67
Peripheral intraneutrophil diplococci in a case of meningococcemia. 66
Clinical significance of somatic mutation in unexplained blood cytopenia 66
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 65
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 64
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 62
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 62
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 61
Cardiovascular events and intensity of treatment in polycythemia vera. 61
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 61
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 60
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 60
Familial chronic myeloproliferative disorders: the state of the art 59
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 59
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 59
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 59
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 59
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 59
Role of the molecular staging and response in the management of follicular lymphoma patients 58
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 58
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 58
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 58
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 58
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 58
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 58
Allelic imbalance in CALR somatic mutagenesis 57
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 57
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 56
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 56
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 56
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 56
Clinical relevance of JAK2 (V617F) mutant allele burden 56
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 54
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 53
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 53
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 53
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 53
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 52
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 52
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 52
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 52
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 51
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 51
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 51
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 50
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 50
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 49
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 49
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 49
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 49
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 48
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 48
Mutational status of myeloproliferative neoplasms. 47
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 47
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 47
Improving survival trends in primary myelofibrosis: an international study. 47
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 46
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 46
Mutations and prognosis in primary myelofibrosis 45
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 45
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 45
Diagnosis and management of prefibrotic myelofibrosis. 45
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 44
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 44
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 44
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 43
Myelofibrotic transformation in essentialthrombocythemia. Author reply 43
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene 43
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms 43
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. 43
LNK mutations in familial myeloproliferative neoplasms. 43
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 42
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 42
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 42
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 41
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 41
Somatic mutations of calreticulin in myeloproliferative neoplasms 41
Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib 40
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 39
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT. 39
How I treat essential thrombocythemia. 39
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. 39
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 38
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 38
Masked polycythemia vera diagnosed according to WHO and BCSH classification 38
Totale 5.478
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020391 0 0 0 0 0 60 18 95 27 146 41 4
2020/2021605 74 48 13 62 4 62 10 106 53 89 66 18
2021/2022693 9 4 23 11 17 38 6 38 33 38 115 361
2022/20232.091 223 118 21 135 204 169 1 100 992 13 87 28
2023/20241.055 119 170 55 70 96 302 27 66 10 22 76 42
2024/2025578 66 209 72 61 56 114 0 0 0 0 0 0
Totale 7.571